AbbVie Inc. vs Bristol-Myers Squibb Company: SG&A Expense Trends

SG&A Expense Trends: AbbVie Inc. vs Bristol-Myers Squibb Company

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, AbbVie Inc. and Bristol-Myers Squibb Company have demonstrated distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AbbVie Inc. saw a significant increase of approximately 66% in SG&A expenses, peaking in 2022. This rise reflects strategic investments in marketing and administrative capabilities. In contrast, Bristol-Myers Squibb's SG&A expenses grew by about 37% over the same period, indicating a more conservative approach. Notably, both companies experienced a sharp rise in 2020, likely due to pandemic-related adjustments. These trends highlight the differing financial strategies of these pharmaceutical giants, offering insights into their operational priorities and market positioning.